B-cell lymphoma phase 1 clinical trial results demonstrate the effectiveness of third-generation anti-CD19 CAR T-cells without causing neurotoxicity.

Published Date: 13 Dec 2023

Today, the phase 1 dose escalation trial results for a new third generation anti-CD19 chimeric antigen receptor were released by the Malaghan Institute of Medical Research and Wellington Zhaotai Therapies Limited.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: When will individuals be able to receive customized cancer vaccines?

2.

Canadian Group Calls for Earlier Colorectal Cancer Screening

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

5.

Talquetamab Combos Show Survival Benefit in r/r Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot